Recruitment is ongoing at several sites in the U.S.
First patient has been dosed.
Topline data from the trial is expected in the first half of 2026.
PNT article: Dosing begins in Phase 3 trial of Parkinson’s therapy solengepras.
Update from Cerevance on the Phase 3 tria... - Cure Parkinson's
Update from Cerevance on the Phase 3 trial of their GPR6 inverse agonist CVN424 (solengepras)
Written by
jeffreyn
To view profiles and participate in discussions please or .
Not what you're looking for?
You may also like...
Positive results for Cerevance’s Parkinson’s drug, phase 2 of CVN424 a GPR6 inverse agonist
In phase 2 trials, the drug reduced ‘OFF time’ which refers to periods of the day when Parkinson’s...
Phase 3 trial of buntanetap for early-stage Parkinson’s nears end
Phase 3 trial of buntanetap for early-stage Parkinson’s nears end – The last patient completed the...
Anyone participating in the Buntanetap Phase 3 trial?
Would love to hear your initial feedback. I'm considering participating. Full info here:...
UPDATE on phase 3 clinical trial progress from Zhittya Genesis Medicine
I know some of you are very skeptical about this company (I have some doubts but I'm crossing my...
Phase 1 trial of VRG50635 - a novel therapeutic discovered & "delivered into the clinic in just 4 years" by an AI-powered platform
I know it is for ALS but it gives me hope that AI can deliver so fast....
Related Posts
Annovis Bio Announces Approval for EU Clinical Trial Sites for the Phase 3 Study of Buntanetap for the Treatment of Parkinson's Disease- A (minor) update by Inhibikase Therapeutics on their Phase 2 trial of Risvodetinib (IkT-148009) for Parkinson's Disease.
- Update on BlueRock Therapeutics stem-cell Phase 1 trial (which uses Human Embryonic Stem Cell-Derived Midbrain Dopamine Neurons)
- SoPD blog post from Simon on the recent results from the NADPARK trial of nicotinamide riboside (Niagen)
Clinical Trial Highlights – an update on previously reviewed trials (Phase 3 in focus)
